Rigel Pharmaceuticals Inc
RIGL· Nasdaq
RIGLRigel Pharmaceuticals Inc
Released May 6, 2025, after the close
10-Q filed May 6, 2025, 36 days after period end · 0001558370-25-006493
| Metric | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 |
|---|---|---|---|---|
| Revenue | $53.33M | $29.53M | $26.07M | $16.74M |
| Net Income | $11.45M | -$8.25M | -$13.54M | -$27.45M |
| EPS Diluted |
Rigel Pharmaceuticals Inc · CIK 1034842 · Engraved from SEC EDGAR
| $0.63 |
| -$0.47 |
| -$0.08 |
| -$0.16 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
